Recalcitrant Issues and New Frontiers in Nano-Pharmacology.

Clicks: 291
ID: 77273
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Packaging of old pharma drugs into new packaging "nanoparticles" is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only ∼20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers, and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.
Reference Key
bhardwaj2019recalcitrantfrontiers Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bhardwaj, Vinay;Kaushik, Ajeet;Khatib, Ziad M;Nair, Madhavan;McGoron, Anthony J;
Journal Frontiers in pharmacology
Year 2019
DOI
10.3389/fphar.2019.01369
URL
Keywords
nanoparticles research and development nanomedicine theranostics doxil nano-based drugs

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.